XML 42 R18.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Note 8 - Earnings Per Share | 12 Months Ended
--- | ---
Dec. 31, 2024
Notes to Financial Statements |
Earnings Per Share [Text Block] | Note 8 – Earning Per Share The following table summarizes the earnings and the weighted average number of common shares used in the calculation of basic and diluted earnings per share (in thousands, except share and per share amounts):
|  | Year Ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
Basic: |  |  |  |  |  |  |  |  |  |  |  |
Weighted average common shares outstanding |  |  | 15,393,782 |  |  |  | 15,310,142 |  |  |  | 15,410,222 |
Net income attributable to common stockholders of National Healthcare Corporation |  | $ | 101,927 |  |  | $ | 66,798 |  |  | $ | 22,445 |
Earnings per common share, basic |  | $ | 6.62 |  |  | $ | 4.36 |  |  | $ | 1.46 |
Diluted: |  |  |  |  |  |  |  |  |  |  |  |
Weighted average common shares outstanding |  |  | 15,393,782 |  |  |  | 15,310,142 |  |  |  | 15,410,222 |
Dilutive effect of stock options |  |  | 204,746 |  |  |  | 67,201 |  |  |  | 36,989 |
Assumed average common shares outstanding |  |  | 15,598,528 |  |  |  | 15,377,343 |  |  |  | 15,447,211 |
Net income attributable to common stockholders of National Healthcare Corporation |  | $ | 101,927 |  |  | $ | 66,798 |  |  | $ | 22,445 |
Earnings per common share, diluted |  | $ | 6.53 |  |  | $ | 4.34 |  |  | $ | 1.45 |
For the years ended December 31, 2024 and 2023, there were no stock options excluded from the calculation of diluted weighted average shares of common stock outstanding. For the year ended December 31, 2022, 375,638 stock options were excluded from the calculation of diluted weighted average shares of common stock outstanding because the inclusion of these securities would have an anti-dilutive effect.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration